Single technology appraisal: cost-comparison

User guide for company evidence submission template

# January 2022

# Instructions for companies

This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) when a cost-comparison case is made as part of the single technology appraisal process. It explains what information NICE requires and the format in which it should be presented.

Information should be submitted in the cost-comparison [company evidence submission template](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance). Companies making evidence submissions to NICE should also refer to the NICE [health technology evaluation guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation).

The submission should be as brief and informative as possible. The main body of the submission must not be longer than 100 pages, excluding the appendices and the pages covered by the template.

The submission should be sent to NICE electronically in Word or a compatible format, and not as a PDF file. The submission must be a stand-alone document. Some of the information we request should be submitted as appendices to the main submission (when this is the case, it is clearly marked). The information in these appendices is required by the external assessment group (EAG) to fully critique the submission. The appendices are not normally presented to the appraisal committee, but will be available to them on request.

When making an evidence submission, companies must ensure that:

* All confidential information is highlighted and underlined in the electronic version sent to NICE.
* An executable electronic copy of the economic model is included in the version sent to NICE, with full access to the programming code. The content of the evidence submission and the content of the economic model should match.
* The checklist of confidential information (provided by NICE with the invitation to submit) is completed and submitted.

See section 5.3 and 5.4 of the NICE [health technology evaluation guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation) for information about all aspects of information handling.

To ensure that the appraisal process is as transparent as possible, NICE considers that evidence on which the appraisal committee’s decisions are based should be publicly available.

NICE requires the medical director of the company to sign a statement confirming that all clinical trial data necessary to address the remit and scope of the technology appraisal as issued by the Department of Health and Social Care and NICE, within the company's or any of its associated companies’ possession, custody, or control in the UK, or elsewhere in the world, have been disclosed.

NICE considers that the definition of ‘all clinical trial data’ is not limited to conventional randomised controlled trials (RCTs), but is meant to include other types of interventional or observational clinical research methodologies, such as large simple trials, cohort studies, case control studies, or registry data. This definition is consistent with that used by the European Medicines Agency in its [policy on publication of clinical data on medicinal products for human use](http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000555.jsp&mid=WC0b01ac0580607bfa).

NICE requires companies to consent to European Economic Area regulatory authorities directly providing NICE with all clinical trial data necessary to address the remit and scope of the technology appraisal as issued by the Department of Health and Social Care and NICE. This includes all data that have been submitted to the regulatory authorities by the company or any of its associated companies and that were relevant to the granting of a marketing authorisation, and for NICE to use those data in carrying out the technology appraisal. NICE will only ask regulatory authorities directly after having first approached the company for the information and the company is unable or unwilling to provide the information in a timely manner.

All information that should be provided in an appendix is outlined in the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance)

* + - 1. Decision problem, description of the technology and clinical care pathway
	1. Decision problem

Please choose the most appropriate option(s) from those provided in the submission template about whether the submission covers:

* all or only part of the technology’s marketing authorisation for this indication
* all or only part of the population for whom the comparator has been recommended by NICE.

Present the decision problem in the table in section 1.1 of the template, making reference to the final NICE scope.

* 1. Description of technology being evaluated

Provide details of the technology being evaluated using the table in section 1.1 of the template.

* 1. Health condition and position of the technology in the treatment pathway
		1. Present the clinical pathway of care that shows the context and the proposed placement of the technology within the pathway. This information should be summarised in a diagram if possible. If a relevant NICE guideline has been published, the response to this point should be consistent with the guideline and any differences should be explained. If the management of the condition has changed since the NICE technology appraisal(s) of the comparator(s) specified in the final scope, highlight and explain the differences.
	2. **Equality considerations**
		1. NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. For further information about equality issues see NICE’s [equality scheme](https://www.nice.org.uk/about/who-we-are/policies-and-procedures/nice-equality-scheme).
		2. Provide an assessment of whether the use of this technology is likely to raise any equality issues. Please document any potential issues that:
* could exclude from full consideration any people protected by the equality legislation who fall within the patient population for whom the technology is or will be licensed
* could lead to recommendations that have a different impact on people protected by the equality legislation compared with the wider population, for example, by making it more difficult in practice for a specific group to access the technology
* could lead to recommendations that have any adverse impact on people with a particular disability or disabilities.
	+ 1. Please provide any evidence that would enable the committee to identify and consider the impact of equality issues. State how the analysis has addressed these issues.
			1. Key drivers of the cost effectiveness of the comparators
	1. Clinical outcomes and measures

To inform the appraisal committee’s evaluation of whether the technology provides similar or greater overall health benefits than the comparator(s) specified in the NICE scope and relevant to the decision problem, it is important that the evidence base for the technology includes the same outcomes and the same measurement scales that were used in the NICE technology appraisal(s) of these comparator(s). The purpose of section 2.1 of the submission is to identify the relevant outcome measures and highlight which ones were important in estimating the cost effectiveness of the comparator(s), that is, which clinical outcomes the model was sensitive to. A suggested format for presenting this information is provided below.

### Table [X] Clinical outcomes and measures appraised in published NICE guidance for the comparator(s)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Outcome** | **Measurement scale** | **Used in cost-effectiveness model?** | **Impact on ICER\***  | **Committee’s preferred assumptions** | **Uncertainties** |
| **NICE TAXXX** |  |  |  |  |  |  |
| **NICE TAXXX** |  |  |  |  |  |  |
| **NICE TAXXX** |  |  |  |  |  |  |
| **[Add more rows as needed]** |  |  |  |  |  |  |

\*Was the ICER sensitive to changes in this outcome? How did changes in the outcome affect the ICER (increase or decrease)?

Abbreviations: TA; technology appraisal, ICER; incremental cost-effectiveness ratio

* 1. Resource use assumptions

The purpose of section 2.2 of the submission is to identify the cost data and sources that were considered appropriate in the published NICE guidance for the comparator(s) specified in the NICE scope and relevant to the decision problem. This should inform the selection of data and sources for the cost-comparison analysis.

* + 1. Summarise the committee’s preferred assumptions about resource use and the associated costs from the NICE technology appraisal(s) of the comparator(s) relevant to the decision problem, for example, the frequency of monitoring visits. Describe any uncertainties in the assumptions and estimates used in the previous NICE appraisal(s).
			1. Clinical effectiveness

Section 3 provides detailed guidance on the level of information that should be included in the evidence submission template about the clinical effectiveness of the appraised technology.

Evidence on outcomes should be obtained from a systematic review, defined as systematically locating, including, appraising and synthesising the evidence to obtain a reliable and valid overview of the data.

When completing the template, also refer to the NICE [health technology evaluation guidance development manual (section 3)](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation).

For further information on how to implement the approaches described in the NICE methods guide, see the [technical support documents produced by the NICE Decision Support Unit](http://www.nicedsu.org.uk/evidence-synthesis-tsd-series%282391675%29.htm) about evidence synthesis:

* Introduction to evidence synthesis for decision making (technical support document 1).
* A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials (technical support document 2).
* Heterogeneity: subgroups, meta-regression, bias and bias-adjustment (technical support document 3).
* Inconsistency in networks of evidence based on randomised controlled trials (technical support document 4).
* Evidence synthesis in the baseline natural history model (technical support document 5).
* Embedding evidence synthesis in probabilistic cost-effectiveness analysis: software choices (technical support document 6).
* Evidence synthesis of treatment efficacy in decision making: A reviewer’s checklist (technical support document 7).
* Methods for population-adjusted indirect comparisons in submissions to NICE (technical support document 18).

Although the Decision Support Unit is funded by NICE, technical support documents are not formal NICE guidance or policy.

* 1. Identification and selection of relevant studies

This section provides guidance on identifying and selecting relevant studies that provide evidence for:

* the technology being evaluated
* comparator technologies, when an indirect or mixed treatment comparison is carried out.

 This information should be submitted as **appendix** **D** to the main submission. See the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance).

* 1. List of relevant clinical effectiveness evidence

NICE prefers RCTs that directly compare the technology with 1 or more relevant comparators. However, such evidence may not always be available and may not be sufficient to quantify the effect of treatment over the course of the disease. Therefore, data from non-randomised and non-controlled studies may be needed to supplement RCT data. In addition, data from trials that compare the technology with non-relevant comparators may be needed to enable the technology and the comparators to be linked in an indirect or mixed treatment comparison. Please provide details of the RCTs and non-randomised and non-controlled trials identified in the systematic literature review for the technology being appraised. A suggested table format for each source of evidence is given below. Indicate whether the trial was used to support the application for marketing authorisation.

### Table [X] Clinical effectiveness evidence

| **Study**  | [Clinical trial name or primary author surname (year published)] |
| --- | --- |
| **Study design** |  |
| **Population** |  |
| **Intervention(s)** |  |
| **Comparator(s)** |  |
| **Indicate if study supports application for marketing authorisation (yes/no)** |  |
| **Reported outcomes specified in the decision problem** |  |
| **All other reported outcomes** |  |

* 1. Summary of methodology of the relevant clinical effectiveness evidence

It is expected that all key aspects of methodology will be in the public domain; if a company wishes to submit aspects of the methodology in confidence, prior agreement must be obtained from NICE.

* + 1. Items 3 to 6b of the [CONSORT checklist](http://www.consort-statement.org/) should be provided for all RCTs identified in section 3.2.
* **Trial design** – brief description of trial design, including details of randomisation if applicable.
* **Eligibility criteria** – a comprehensive description of the eligibility criteria used to select the trial participants, including any definitions and any assessments used in recruitment.
* **Settings and locations where the data were collected** – describe the locations where the trial was carried out, including the country and, if applicable, the care setting (for example, primary care [GP or practice nurse], secondary care [inpatient, outpatient, day case]).
* **Trial drugs and concomitant medications** – provide details of trial drugs and comparator(s), with dosing information and titration schedules if appropriate. Provide an overview of concomitant medications permitted and disallowed during the trial.
* **Outcomes specified in the scope –** please state if the outcomes were pre-specified or post-hoc analyses.
	+ 1. Provide a comparative summary of the methodology of the trials in a table. A suggested table format is presented below.

### Table [X] Comparative summary of trial methodology

|  |  |  |  |
| --- | --- | --- | --- |
| **Trial number****(acronym)**  | **Trial 1** | **Trial 2** | **[Add more columns as needed]** |
| **Location** |  |  |  |
| **Trial design**  |  |  |  |
| **Eligibility criteria for participants** |  |  |  |
| **Settings and locations where the data were collected** |  |  |  |
| **Trial drugs (the interventions for each group with sufficient details to allow replication, including how and when they were administered)****Intervention(s) (n=[x]) and comparator(s) (n=[x])****Permitted and disallowed concomitant medication** |  |  |  |
| **Primary outcomes (including scoring methods and timings of assessments)**  |  |  |  |
| **Pre-planned subgroups** |  |  |  |

* + 1. In a table describe the characteristics of the participants at baseline for each of the trials in your submission. Provide details of baseline demographics, including age, sex and relevant variables describing disease severity and duration and appropriate previous treatments and concomitant treatment. Highlight any differences between trial groups. A suggested table format is presented below.

### Table [X] Characteristics of participants in the studies across treatment groups

|  |  |  |  |
| --- | --- | --- | --- |
| **Trial number (acronym)****Baseline characteristic** | **Treatment group X** | **Treatment group Y** | **[Add more columns as needed]** |
| **Trial 1 (n=[x])** | (n=[x]) | (n=[x]) | (n=[x]) |
| **Age** |  |  |  |
| **Sex**  |  |  |  |
| **[Add more rows as needed]** |  |  |  |
| **Trial 2 (n=[x])** | (n=[x]) | (n=[x]) | (n=[x]) |
| **Age** |  |  |  |
| **Sex**  |  |  |  |
| **[Add more rows as needed]** |  |  |  |

Adapted from Pharmaceutical Benefits Advisory Committee (2008) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Pharmaceutical Benefits Advisory Committee

* + 1. Clearly describe the methods used for expert elicitation or expert opinion, including the identification and selection of experts, and the reporting of results including the consensus of opinions or data aggregation. Follow existing reporting guidelines when possible.
		2. See section 3.3.14 of [NICE’s health technology guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation) for additional guidance on the design, conduct and reporting of non-randomised and real-world studies.
	1. Statistical analysis and definition of study groups in the relevant clinical effectiveness evidence
		1. During completion of this section consider items 7a (sample size), 7b (interim analyses and stopping guidelines), 12a (statistical methods used to compare groups for primary and secondary outcomes) and 12b (methods for additional analyses, such as subgroup analyses and adjusted analyses) of the [CONSORT checklist](http://www.consort-statement.org/).
		2. For each trial identified in section 3.2, provide details of the trial population included in the primary analysis of the primary outcome and methods used to take account of missing data (for example, a description of the intention-to-treat analysis carried out, including censoring methods, or whether a per-protocol analysis was carried out).
		3. For each trial, provide details of the statistical tests used in the primary analysis. Also provide details of the primary hypothesis or hypotheses under consideration, the power of the trial and a description of sample size calculation, including rationale and assumptions in a table. State whether each trial was designed as a superiority, equivalence or non-inferiority trial; state the equivalence boundary and non-inferiority margin where relevant. Justify non-inferiority margins selected, in relation to clinically important differences. If the outcomes were adjusted for covariates, provide the rationale. A suggested table format is presented below.
		4. For non-randomised and non-controlled evidence such as observational studies, the potential biases should be identified before data analysis, either by a thorough review of the subject area or discussion with experts in the clinical discipline. Ideally these should be quantified and adjusted for.

### Table [X] Summary of statistical analyses

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Trial number (acronym)** | **Hypothesis objective\*** | **Statistical analysis** | **Sample size, power calculation**  | **Data management, patient withdrawals** |
| **Trial 1** |  |  |  |  |
| **Trial 2** |  |  |  |  |
| **[Add more rows as needed]** |  |  |  |  |

\*Include whether the hypothesis was tested as superiority, equivalence or non-inferiority trial

### Participant flow in the relevant randomised controlled trials

See **appendix** **D** to the main submission in the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances) for details of additional information that should be provided.

* 1. Critical appraisal of the relevant clinical effectiveness evidence

In **appendix D**, provide the complete quality assessment for each trial. See the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances) for details.

* + 1. The validity of the results of an individual RCT or non-randomised or non-controlled study will depend on the robustness of its overall design and execution, and its relevance to the decision problem. The quality of each source of evidence identified in section 3.2 should be appraised. Whenever possible, the criteria for assessing published studies should be used to assess the validity of unpublished and part-published studies. The quality assessment will be validated by the ERG.
		2. Describe the methods used for assessing risk of bias and generalisability of individual trials (including whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
* The following are the minimum criteria for assessment of risk of bias and generalisability in parallel group RCTs, but the list is not exhaustive:
	+ Was the randomisation method adequate?
	+ Was the allocation adequately concealed?
	+ Were the groups similar at the outset of the study in terms of prognostic factors, for example severity of disease?
	+ Were the care providers, participants and outcome assessors blind to treatment allocation? If any of these people were not blind to treatment allocation, what might be the likely impact on the risk of bias (for each outcome)?
	+ Were there any unexpected imbalances in drop-outs between groups? If so, were they explained or adjusted for?
	+ Is there any evidence to suggest that the authors measured more outcomes than they reported?
	+ Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data?
* Also consider whether the authors of the study publications declared any conflicts of interest.
* In addition to parallel group RCTs, there are other randomised designs (for example, randomised crossover trials and randomised cluster trials) in which further quality criteria may need to be considered when assessing bias. Key aspects of quality to be considered can be found in [Systematic reviews: CRD’s guidance for undertaking reviews in health care](https://www.york.ac.uk/crd/) (University of York Centre for Reviews and Dissemination).
* For the quality assessments of non-randomised and non-controlled evidence, use an appropriate and validated quality assessment instrument. Key aspects of quality to be considered can be found in Systematic reviews: CRD’s guidance for undertaking reviews in health care (University of York Centre for Reviews and Dissemination). This includes information on a number of initiatives aimed at improving the quality of research reporting.
	+ 1. Consider how closely the trials reflect routine clinical practice in England.
		2. If there is more than 1 trial, tabulate a summary of the responses applied to each of the quality assessment criteria. A suggested table format for the quality assessment results is given below.

### Table [X] Quality assessment results for parallel group RCTs

|  |  |  |  |
| --- | --- | --- | --- |
| **Trial number (acronym)** | **Trial 1** | **Trial 2** | **[Add more columns as needed]** |
| Was randomisation carried out appropriately? | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |
| Was the concealment of treatment allocation adequate? | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |
| Were the groups similar at the outset of the study in terms of prognostic factors?  | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |
| Were the care providers, participants and outcome assessors blind to treatment allocation? | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |
| Were there any unexpected imbalances in drop-outs between groups? | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |
| Is there any evidence to suggest that the authors measured more outcomes than they reported? | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |
| Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data? | (yes/no/not clear/N/A)  | (yes/no/not clear/N/A)  |  |

Adapted from Systematic reviews: CRD’s guidance for undertaking reviews in health care (University of York Centre for Reviews and Dissemination)

* 1. Clinical effectiveness results of the relevant trials
		1. Present results for all outcomes that are important to the decision problem, from the trials identified in section 3.2. These must include outcomes and measures that were used in the cost-effectiveness analysis of the NICE technology appraisal(s) of the comparator(s) specified in the final scope, focusing on any outcomes that the model was sensitive to. Normally, the committee will consider only the same outcome measures as were used in the NICE technology appraisal(s) for the comparator(s). Different outcome measures will be accepted if an empirical mapping tool is available.
		2. Data from intention-to-treat analyses should be presented whenever possible and a definition of the included participants provided. If participants have been excluded from the analysis, the rationale for this should be given. Per-protocol analyses should be presented in addition to intention-to-treat analyses where relevant to the study design and hypothesis. Explain any discrepancies between the intention-to-treat and per-protocol analyses.
		3. The information may be presented graphically to supplement text and tabulated data. If appropriate, please present graphs such as Kaplan–Meier plots.
		4. For each outcome, provide the following information from each study:
* The unit of measurement.
* The size of the effect; for dichotomous outcomes, the results ideally should be expressed both as relative risks (or odds ratios) and risk (or rate) differences. For time-to-event analysis, the hazard ratio is an equivalent statistic. Both absolute and relative data should be presented.
* A 95% confidence interval.
* The number of people in each group included in each analysis and whether the analysis was intention-to-treat or per-protocol. State the results in absolute numbers when feasible.
* When interim data are quoted, this should be clearly stated, along with the point at which data were taken and the time remaining until completion of the trial. Analytical adjustments should be described to cater for the interim nature of the data.
* Other relevant data that may help interpret the results may be included, such as adherence to medication or study protocol.
* Discuss and justify any clinically important differences in the results between the different arms of a trial and between trials.
* Specify whether unadjusted and adjusted analyses were performed, and whether the results were consistent.
	1. Subgroup analysis

This section should be read with the NICE [health technology evaluation guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation) section 4.9. Only provide results of subgroup analyses if the technology does not provide similar or greater health benefits at a similar or lower cost to the comparator in the full population for whom the comparator has been recommended by NICE.

* + 1. Provide details of the subgroup analyses carried out. Specify the rationale and whether they were pre-planned or post-hoc.
		2. Clearly specify the characteristics of the participants in the subgroups and explain the appropriateness of the analysis to the decision problem.
		3. Provide details of the statistical tests used in the primary analysis of the subgroups, including any tests for interaction.

Provide a summary of the results for the subgroups in **appendix E**. See the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances) for details.

* 1. Meta-analysis

This section should be read with the [NICE’s health technology evaluation guidance development manual, sections 3.4.8 to 3.4.10](https://www.nice.org.uk/process/pmg36/chapter/evidence#synthesis-of-evidence). For further information on how to implement the approaches described in the manual, see the series of [technical support documents produced by the NICE Decision Support Unit](http://nicedsu.org.uk/technical-support-documents/evidence-synthesis-tsd-series/) about evidence synthesis. See also [technical support document 20](http://nicedsu.org.uk/multivariate-meta-analysis-tsd/).

* + 1. If a meta-analysis cannot be conducted and instead a qualitative overview is considered appropriate, summarise the overall results of the individual studies with reference to their critical appraisal.
		2. If a meta-analysis has been performed, include the following in the results:
* The characteristics and possible limitations of the data (that is, population, intervention, setting, sample sizes and the validity of the evidence) should be fully reported for each study included in the analysis and a forest plot included.
* A statistical assessment of heterogeneity. If the visual presentation and/or the statistical test indicate that the RCT results are heterogeneous, try to explain the heterogeneity.
* Statistically combine (pool) the results for both relative risk reduction and absolute risk reduction using either a fixed effects or random effects model as appropriate.
* Provide an adequate description of the methods of statistical combination and justify their choice.
* Carry out sensitivity analysis when appropriate.
* Tabulate and/or graphically display the individual and combined results (such as through the use of forest plots).
	+ 1. If any of the relevant studies listed in section 3.1 are excluded from the meta-analysis, the reasons for doing so should be explained. The impact that each excluded study has on the overall meta-analysis should be explored.
	1. Indirect and mixed treatment comparisons
		1. In a table provide a summary of the trials used to carry out the indirect comparison or mixed treatment comparison. There is a suggested table format below. When there are more than 2 treatments in the comparator sets for synthesis, include a network diagram. For studies involving comparator treatments, state whether the publication was included in the published NICE technology appraisal(s) for each comparator treatment.

### Table [X] Summary of the trials used to carry out the indirect or mixed treatment comparison

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **References of trial** | **Intervention A** | **Intervention B** | **Intervention C** | **Intervention D** |
| **Trial 1** | 🗸 |  | 🗸 | 🗸 |
| **Trial 2** |  | 🗸 | 🗸 | 🗸 |
| **Trial 3** | 🗸 | 🗸 |  |  |
| **Trial 4** | 🗸 |  | 🗸 |  |
| **[Add more rows as needed]** |  |  |  |  |

* + 1. If the table or network diagram provided does not include all the trials that were identified in the search strategy, the rationale for exclusion should be provided.

Full details of the methodology for the indirect comparison or mixed treatment comparison should be presented in **appendix D**. See the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances) for details.

* + 1. Provide the results of the analysis. For examples of how to present the results of the analysis, see the [NICE Decision Support Unit technical support documents 1 to 3](http://nicedsu.org.uk/technical-support-documents/technical-support-documents/)..
		2. Provide the results of the statistical assessment of heterogeneity. The degree of heterogeneity, and the reasons for it, should be explored as fully as possible.
		3. If there is doubt about the relevance of particular trials, present separate sensitivity analyses in which these trials are excluded.
		4. Discuss any heterogeneity between results of pairwise comparisons and inconsistencies between the direct and indirect evidence on the technologies.
	1. Adverse reactions
		1. Evidence from comparative RCTs and regulatory summaries is preferred, but findings from non-comparative trials may sometimes be relevant. For example, post-marketing surveillance data may demonstrate that the technology shows a relative lack of adverse reactions commonly associated with the comparator, or that the occurrence of adverse reactions is not statistically significantly different to those associated with other treatments.
		2. In a table, summarise the adverse reactions reported in the studies identified in section 3.2. For each intervention group, give the number with the adverse reaction and the frequency, the number in the group, and the percentage with the adverse reaction. Then present the relative risk and risk difference and associated 95% confidence intervals for each adverse reaction.

In **appendix F**, provide details of any studies that report additional adverse reactions to those reported by the studies identified in section 2.2. See the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances) for details.

* + 1. Provide a brief conclusion of the safety of the technology in relation to the decision problem. Comment on the similarities and differences between the technology under appraisal and its comparator(s), with respect to adverse reactions. Provide evidence to confirm whether any differences are statistically significant or clinically meaningful.
	1. Conclusions about comparable health benefits and safety
		1. Draw conclusions from the evidence supporting superiority, similarity, non-inferiority or equivalence of the technology compared with the comparator(s) specified in the final scope issued by NICE, including any subgroups. Focus on the key outcomes and measures that were used in the cost-effectiveness analysis of the NICE technology appraisal(s) of the comparator(s) (detailed in section 2).
		2. If there are differences in effectiveness between the technology and its comparator(s), comment on whether these are clinically meaningful and provide supporting evidence.
		3. Provide evidence on the clinical or biological plausibility of similarities in health benefits between the technology and the comparator(s).
		4. Refer back to the committee’s preferred clinical assumptions from the NICE technology appraisal(s) of the comparator(s) outlined in section 2.1, focusing on key drivers of the cost-effectiveness results, and comment on whether similar assumptions can be made for the technology under appraisal. For example:
* Issue from previous appraisal: duration of treatment effect was a key driver of cost effectiveness.
* Committee’s conclusion: duration of treatment effect wanes over time.
* Assumption for new technology and justification: treatment effect also wanes over time similar to the original technology (cross reference the section of the submission that provides supporting evidence).
	+ 1. Describe and explain any uncertainties in the evidence informing your conclusions.
	1. Ongoing studies
		1. Provide details of all completed and ongoing studies that should provide additional evidence in the next 12 months for the indication being appraised.
			1. Cost-comparison analysis

When completing the template, also refer to [NICE’s health technology evaluation guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation).

* 1. Changes in service provision and management

This purpose of this section is to present a descriptive summary; quantification of resource use and the associated costs should be presented in section 4.2. Include cross references to other sections where relevant.

* + 1. Describe the location or setting of care (that is, primary and/or secondary care, commissioned by NHS England specialised services and/or clinical commissioning groups). If this differs from the location or setting of care for the comparators listed in the final scope from NICE, describe these differences.
		2. Identify the main resource use to the NHS associated with the technology being appraised.
		3. Describe any differences in resource use between the technology and the comparators listed in the final scope from NICE. For example, differences in frequency of administration, monitoring and follow-up. Provide details of additional tests or investigations needed, and any additional infrastructure requirements.
	1. Cost-comparison inputs and assumptions

### Features of the cost-comparison analysis

* + 1. State the time horizon used in the cost-comparison analysis, and the rationale for the chosen time horizon. The time horizon should be long enough to reflect materially important differences between the technologies being compared:
* As a minimum, this must include acquisition costs of the technologies. If other relevant differences in costs or resource use are identified, these may also be included (for example, drug administration, time on treatment, monitoring and healthcare appointments).
* If there are relevant differences in health outcomes that affect resource use (for example, managing adverse events), the time horizon must be long enough to capture these. Substantial differences between technologies in costs directly relating to health outcomes (such as adverse events) indicate that the intervention and comparator(s) may not provide similar overall health benefits, so any such cost differences must be clearly justified.
	+ 1. State whether costs were discounted. Discounting of costs is not normally required in a cost-comparison analysis, but can be applied if relevant. If a discount rate is applied, include the rationale.

### Intervention and comparators’ acquisition costs

* + 1. In a table, present the acquisition costs of the intervention and comparator technologies included in the cost-comparison analysis. A suggested format for the table is provided in the submission template. Indicate whether the acquisition costs represent list prices or include a patient access scheme or other nationally available price reduction (for example, through contracts negotiated by the NHS Commercial Medicines Unit).
		2. When an intervention has a patient access scheme/commercial arrangement that has been agreed with NHS England, or when there is another form of nationally available reduction to the list price, these should be included in the base-case analysis to best reflect the prices relevant to the NHS.
		3. If a comparator technology has a patient access scheme or nationally available price reduction that is confidential, the list prices should be presented here.

### Intervention and comparators’ healthcare resource use and associated costs

* + 1. In a table, present the healthcare resource costs associated with the intervention and comparator technologies included in the cost-comparison analysis, and the methods used to estimate them. This should include, where relevant, the costs associated with drug administration, patient monitoring and patient follow-up. A suggested format for the table is provided in the submission template. Costs should be based on use in line with the summary of product characteristics for the new technology (if available) and the comparator(s), and relevant costs included in the published appraisal(s) of the comparator(s). Whenever possible and appropriate, cost data and data sources should be consistent with any corresponding data and sources that were considered appropriate in the published NICE guidance for the comparator(s) for the same indication, but should reflect the most up-to-date information available from these sources. Refer to section 4.4 of [NICE’s health technology evaluation guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation) for guidance on resource costs that are relevant to the NICE reference case.
		2. Identify the unit cost for each resource (for example, cost per GP or hospital appointment £XX, cost per blood test £XX and cost per MRI scan £XX). Justify why that cost was chosen, together with a supporting reference and the price year.
		3. Estimate the value of each resource for each technology (that is, the quantity of resources affected multiplied by their unit cost). Justify the quantity of resources estimated.
* In **appendix G** describe how relevant cost and healthcare resource use data for England were identified.
* In **appendix H** provide the relevant details for each treatment, including the intervention, comparator and subsequent treatments used in the model, including concomitant treatments.

See the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances) for details.

* + 1. When describing how relevant unit costs were identified, comment on whether NHS reference costs or payment-by-results (PbR) tariffs are appropriate for costing the intervention being appraised. Describe how the clinical management of the condition is currently costed in the NHS in terms of reference costs and the PbR tariff. Provide the relevant Healthcare Resource Groups and PbR codes and justify their selection.

### Adverse reaction unit costs and resource use

* + 1. Describe and tabulate the unit costs and resource use associated with the adverse reactions included in the cost-comparison analysis. For each adverse reaction, provide a breakdown of the costs associated with managing it (including technologies used to treat it, staff costs and hospital costs), with source references for each value. Calculate the total cost of adverse reactions per course of treatment for the intervention and each comparator, and calculate the total cost of adverse events over the full time horizon.
		2. Substantial differences between technologies in costs directly relating to health outcomes such as adverse events may indicate that the intervention and comparator(s) may not provide similar overall health benefits, so any such cost differences must be clearly justified.

### Miscellaneous unit costs and resource use

* + 1. Describe and tabulate any additional costs and healthcare resource use that have not been covered elsewhere (for example, costs relating to subsequent lines of therapy received after disease progression, personal and social services costs). If none, please state.

### Clinical expert validation

* + 1. If clinical experts have assessed the cost and healthcare resource use values available, or approximated any of the values used in the analysis, provide the following details :
* the criteria for selecting the experts
* the number of experts approached
* the number of experts who participated
* declaration of potential conflict(s) of interest from each expert whose opinion was sought
* the background information provided and its consistency with all the evidence provided in the submission
* the method used to collect the opinions
* the medium used to collect opinions (for example, was information gathered by direct interview, telephone interview or self-administered questionnaire?)
* the questions asked
* whether iteration was used in the collation of opinions and if so, how it was used (for example, the Delphi technique).

### Uncertainties in the inputs and assumptions

* + 1. Describe and explain any uncertainties in the cost and resource use estimates described above.
	1. Base-case results

### Table [X] Base-case results

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Technologies** | **Acquisition costs (£)** | **Resource costs (£)** | **Adverse event costs (£)** | **Other costs (£)** | **TOTAL COSTS (£)** |
| **Intervention** |  |  |  |  |  |
| **Comparator 1** |  |  |  |  |  |
| **Comparator 2** |  |  |  |  |  |
| **[Add more rows as needed]** |  |  |  |  |  |

State the time horizon

* 1. Sensitivity and scenario analysis
		1. Describe the impact of varying inputs in the cost-comparison analysis that are subject to uncertainty, as identified in section 4.2. Tabulate the results.
	2. Subgroup analysis

This section should be read with the NICE [health technology evaluation guidance development manual](https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation) section 4.9. Only provide results of subgroup analyses if the technology does not provide similar or greater health benefits at a similar or lower cost to the comparator in the full population for whom the comparator has been recommended by NICE.

* + 1. Please specify whether analysis of subgroups was carried out and how these subgroups were identified, referring to the scope and decision problem specified for the NICE technology appraisal. When specifying how subgroups were identified, confirm whether they were identified based on a prior expectation of different clinical or cost effectiveness because of known, biologically plausible mechanisms, social characteristics or other clearly justified factors. Cross refer to the clinical effectiveness section 3.7.
		2. Clearly define the characteristics of patients in the subgroup.
		3. If subgroup analyses were done, please present the results in tables similar to those in section 4.3.
	1. Interpretation and conclusions of economic evidence
		1. When interpreting and concluding your economic evidence, consider the following:
* Is the economic evaluation relevant to all groups of patients who could potentially use the technology as identified in the decision problem?
* How relevant (generalisable) is the analysis to clinical practice in England?
* What are the main strengths and weaknesses of the evaluation? How might these affect the interpretation of the results?
* What further analyses could be carried out to enhance the robustness or completeness of the results?
	+ - 1. References

Please use a recognised referencing style, such as Harvard or Vancouver. Trials should be identified by the first author or trial ID, rather than by relying on numerical referencing alone (for example, ‘Trial NCT123456/Trial ACRONYM/Jones et al.126’ rather than ‘One trial126’).

Please also provide references as a separate RIS file.

* + - 1. Appendices

Clinical trial reports and protocols must be made available for relevant clinical studies; the remainder must be available on request. The information that NICE requests in appendices is needed by the EAG to fully critique the submission. The appendices are not normally provided to the appraisal committee or published on the NICE website; please send these as separate documents to the main submission.

Appendices should start at C, because document A is the submission summary and document B is the main submission.

All information that should be provided in an appendix is outlined in the [user guide for cost comparison submission appendices](https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidances)

Appendix C: European public assessment report, summary of product characteristics/information for use, scientific discussion or drafts

Appendix D: Identification, selection and synthesis of clinical evidence (see section 3.1)

Appendix E: Subgroup analysis (see section 3.7)

Appendix F: Adverse reactions (see section 3.10)

Appendix G: Cost and healthcare resource identification, measurement and valuation (see section 4.2)

Appendix H: Price details of treatments included in the submission (see section 4.2)

Appendix I: Checklist of confidential information

Any additional appendices should start at appendix J.